Common Contracts

2 similar Underwriting Agreement contracts by Sonnet BioTherapeutics Holdings, Inc.

SONNET BIOTHERAPEUTICS HOLDINGS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • November 6th, 2024 • Sonnet BioTherapeutics Holdings, Inc. • Pharmaceutical preparations • New York

Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to several underwriters named on Schedule I hereto (each, an “Underwriter” and collectively, the “Underwriters”) for which Chardan Capital Markets, LLC is acting as the representative (the “Representative”) of the several Underwriters an aggregate of (i) [ ● ] authorized but unissued shares (the “Firm Shares” or “Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares up to an aggregate of [ ● ] shares of Common Stock at an exercise price of $0.0001 per share (the “Pre-Funded Warrant Shares”), and (iii) warrants (the “Firm Warrants” or “Warrants”) to purchase up to an aggregate of [ ● ] shares of Common Stock (the “Firm Warrant Shares” or “Warrant Shares”). The Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares,

13,888,888 Shares of Common Stock (or Pre-Funded Warrants to Purchase Shares of Common Stock in Lieu Thereof) Warrants to Purchase 27,777,776 Shares of Common Stock SONNET BIOTHERAPEUTICS HOLDINGS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • February 13th, 2023 • Sonnet BioTherapeutics Holdings, Inc. • Pharmaceutical preparations • New York

Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to several underwriters named on Schedule I hereto (each, an “Underwriter” and collectively, the “Underwriters”) for which Chardan Capital Markets, LLC is acting as representative (the “Representative”) (i) an aggregate of 13,888,888 authorized but unissued shares (the “Firm Shares” or “Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) or pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock in lieu thereof at an exercise price of $0.0001 per share (the “Pre-Funded Warrant Shares”), and (ii) warrants (the “Firm Warrants” or “Warrants”) to purchase up to an aggregate of 27,777,776 shares of Common Stock (the “Firm Warrant Shares” or “Warrant Shares”). The Shares, the Underwriter Warrants (as defined below), the Underwriter Warrant Shares (as defined below), the P